Astrazeneca PLC (AZN) Rating Reiterated by Deutsche Bank AG
Astrazeneca PLC (NYSE:AZN)‘s stock had its “buy” rating reaffirmed by equities researchers at Deutsche Bank AG in a research report issued on Monday.
AZN has been the subject of several other reports. Bank of America Corp. set a $41.40 price objective on shares of Astrazeneca PLC and gave the stock a “buy” rating in a research report on Thursday, September 8th. Argus upgraded shares of Astrazeneca PLC from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a research report on Monday, August 29th. Piper Jaffray Cos. started coverage on shares of Astrazeneca PLC in a research report on Friday, September 23rd. They set an “overweight” rating for the company. BNP Paribas cut shares of Astrazeneca PLC from an “outperform” rating to a “neutral” rating in a research report on Tuesday, September 13th. Finally, Berenberg Bank reiterated a “buy” rating on shares of Astrazeneca PLC in a research report on Sunday, September 11th. Three analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. Astrazeneca PLC currently has a consensus rating of “Buy” and an average target price of $37.56.
Shares of Astrazeneca PLC (NYSE:AZN) traded down 0.71% during midday trading on Monday, reaching $32.06. 3,693,999 shares of the company’s stock traded hands. The stock has a market cap of $81.11 billion, a P/E ratio of 36.64 and a beta of 0.75. Astrazeneca PLC has a 12 month low of $26.97 and a 12 month high of $35.04. The stock has a 50 day moving average of $33.19 and a 200-day moving average of $30.86.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/astrazeneca-plc-azn-rating-reiterated-by-deutsche-bank-ag.html
Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.83 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The company earned $5.60 billion during the quarter, compared to analysts’ expectations of $5.56 billion. During the same period in the prior year, the company posted $1.21 earnings per share. Astrazeneca PLC’s revenue for the quarter was down 4.0% compared to the same quarter last year. On average, equities research analysts forecast that Astrazeneca PLC will post $2.97 EPS for the current fiscal year.
The business also recently disclosed a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were given a $0.44 dividend. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio is 78.29%.
Hedge funds have recently made changes to their positions in the company. Dodge & Cox raised its stake in shares of Astrazeneca PLC by 121.2% in the first quarter. Dodge & Cox now owns 26,049,650 shares of the company’s stock valued at $733,558,000 after buying an additional 14,272,518 shares in the last quarter. Primecap Management Co. CA increased its position in Astrazeneca PLC by 1,223.1% in the first quarter. Primecap Management Co. CA now owns 13,084,275 shares of the company’s stock valued at $368,453,000 after buying an additional 12,095,375 shares during the last quarter. Capital International Investors increased its position in Astrazeneca PLC by 22.1% in the second quarter. Capital International Investors now owns 20,473,479 shares of the company’s stock valued at $618,094,000 after buying an additional 3,705,199 shares during the last quarter. BlackRock Investment Management LLC increased its position in Astrazeneca PLC by 73.2% in the second quarter. BlackRock Investment Management LLC now owns 7,207,036 shares of the company’s stock valued at $217,580,000 after buying an additional 3,046,268 shares during the last quarter. Finally, Becker Capital Management Inc. acquired a new position in Astrazeneca PLC during the second quarter valued at $35,701,000. 11.39% of the stock is currently owned by institutional investors and hedge funds.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.